Targeting and engineering long non-coding RNAs for cancer therapy.

Coan, Michela; Haefliger, Simon; Ounzain, Samir; Johnson, Rory (2024). Targeting and engineering long non-coding RNAs for cancer therapy. (In Press). Nature Reviews. Genetics Natue Publishing Group 10.1038/s41576-024-00693-2

Text s41576-024-00693-2.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (4MB) | Request a copy

RNA therapeutics (RNATx) aim to treat diseases, including cancer, by targeting or employing RNA molecules for therapeutic purposes. Amongst the most promising targets are long non-coding RNAs (lncRNAs), which regulate oncogenic molecular networks in a cell type-restricted manner. lncRNAs are distinct from protein-coding genes in important ways that increase their therapeutic potential yet also present hurdles to conventional clinical development. Advances in genome editing, oligonucleotide chemistry, multi-omics and RNA engineering are paving the way for efficient and cost-effective lncRNA-focused drug discovery pipelines. In this Review, we present the emerging field of lncRNA therapeutics for oncology, with emphasis on the unique strengths and challenges of lncRNAs within the broader RNATx framework. We outline the necessary steps for lncRNA therapeutics to deliver effective, durable, tolerable and personalized treatments for cancer.

Interest & Impact

Downloads

0 since deposited on 04 Mar 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item